News25/Ratings12
News · 26 weeks77-82%
2026-03-082026-08-30
Mix4990d
- Insider24(49%)
- SEC Filings13(27%)
- Other5(10%)
- Earnings3(6%)
- Offering3(6%)
- Analyst1(2%)
Latest news
25 items- PRQ32 Bio to Participate in Upcoming September Investor ConferencesWALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September:Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, September 8, 2026Fireside Chat Presentation Time: 3:45 p.m. E.T.Location: Boston, MACantor Global Healthcare Conference 2026Date: Wednesday, September 9, 2026Fireside Chat Presentation Time: 3:55 p.m. E.T.Location: New York, NYMorgan Stanley 24th Annual Global Healthcare ConferenceDate: Tuesday,
- INSIDERCFO and President Kalowski Lee sold $65,776 worth of shares (3,972 units at $16.56), decreasing direct ownership by 3% to 138,471 units (SEC Form 4) (withholding obligation)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERCEO Morrison Jodie Pope sold $163,033 worth of shares (9,845 units at $16.56), decreasing direct ownership by 3% to 343,259 units (SEC Form 4) to satisfy tax liability4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERChief Scientific Officer Violette Shelia M. sold $46,335 worth of shares (2,798 units at $16.56), decreasing direct ownership by 2% to 127,771 units (SEC Form 4) (for tax liability)4 - Q32 Bio Inc. (0001661998) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Q32 Bio with a new price targetMorgan Stanley initiated coverage of Q32 Bio with a rating of Overweight and set a new price target of $34.00
- SECSEC Form 10-Q filed by Q32 Bio Inc.10-Q - Q32 Bio Inc. (0001661998) (Filer)
- SECQ32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 ---- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing ---- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year ---- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development ---- Completed $200 million public offering in July 2026 ---- Cas
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- SECSEC Form EFFECT filed by Q32 Bio Inc.EFFECT - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 424B3 filed by Q32 Bio Inc.424B3 - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Tzianabos Arthur4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Laporte Kathleen4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Lundberg Sven Ante4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Iwicki Mark T4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Xu Diyong4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Manke Isaac4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Grayzel David S.4/A - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Thistle Mary4/A - Q32 Bio Inc. (0001661998) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
- INSIDERChief Scientific Officer Violette Shelia M. was granted 37,500 shares, increasing direct ownership by 40% to 130,569 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERCEO Morrison Jodie Pope was granted 132,000 shares, increasing direct ownership by 60% to 353,104 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERCFO and President Kalowski Lee was granted 53,250 shares, increasing direct ownership by 60% to 142,443 units (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form S-3 filed by Q32 Bio Inc.S-3 - Q32 Bio Inc. (0001661998) (Filer)
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
QTTB FAQ
6 questionsWhere does QTTB stock trade?
Q32 Bio Inc. (QTTB) is listed on NASDAQ.What sector and industry is QTTB in?
Q32 Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Q32 Bio Inc. go public?
Q32 Bio Inc. (QTTB) completed its IPO in 2018.What are analysts saying about QTTB?
Q32 Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight with a $3400.00 price target on 2026-08-24.What companies are similar to QTTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare QTTB side-by-side with any of them on Quantisnow.How can I track QTTB on Quantisnow?
Quantisnow aggregates Q32 Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTTB to receive live email and push alerts on every new disclosure.